All studies
Endocrinology · Claims + EHR · Japan
Wakabayashi 2023
Diabetes
ITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
3
In the analysis
3
all comparisons pooled
Target trials
3
Emulations reported
3
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 PS matching
- Analysis method
- T-distribution (T-test)
- Missing data
- NR
- Covariates adjusted
- 5
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Claims + EHR
- Data sources
- 1
- Geography
- Japan
- Eligible sample
- 96
- Treated
- 48
- Control
- 48
- Emulations
- 3
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Clinical Study Support Inc.
- Funding
- Declared: Research institute, private
- Funders
- Juntendo University, Shin Nippon Biomedical Laboratories, Ltd
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2023_Wakabayashi_Diabetes
- DOI
- https://doi.org/10.1007/s40801-023-00353-7
- Affiliations
- Clinical Study Support, Inc., Nagoya, Japan, Real-World Evidence and Data Assessment (READS), Graduate School of Medicine, Juntendo University, Department of Radiology, School of Medicine, Juntendo University
- Sector
- Academia, Industry
- Target trials (study level)
- PRIME-V
- Registration
- UMIN000015170